{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02679807",
      "orgStudyIdInfo": {
        "id": "18625"
      },
      "organization": {
        "fullName": "University of Virginia",
        "class": "OTHER"
      },
      "briefTitle": "Effect of Probiotic on Rhinovirus Induced Colds",
      "officialTitle": "Effect of Probiotic on Rhinovirus Induced Colds",
      "acronym": "MK EPRIC"
    },
    "descriptionModule": {
      "briefSummary": "This is a randomized, double-blind placebo controlled trial to evaluate the effect of a probiotic (Bl-04) on the occurrence of rhinovirus-associated common cold illness in the experimental rhinovirus challenge model. A previous study documented that Bl-04 has significant effects on the innate immune response in the nose and this study will be powered to assess whether these effects translate into a demonstrable clinical benefit. Volunteers will be given Bl-04 or placebo for 28 days then challenged with rhinovirus. The primary analysis will be on the proportion of volunteers who develop a rhinovirus associated illness in the two treatment groups."
    },
    "conditionsModule": {
      "conditions": [
        "Common Cold"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "PREVENTION",
        "maskingInfo": {
          "masking": "TRIPLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 380,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Bifidobacterium lactis Bl-04",
          "type": "ACTIVE_COMPARATOR",
          "description": "2\\*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier",
          "interventionNames": [
            "Biological: Bifidobacterium animalis subsp. lactis Bl-04"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "sucrose",
          "interventionNames": [
            "Other: sucrose"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Bifidobacterium animalis subsp. lactis Bl-04",
          "armGroupLabels": [
            "Bifidobacterium lactis Bl-04"
          ]
        },
        {
          "type": "OTHER",
          "name": "sucrose",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Participants With Rhinovirus-associated Illness Episodes",
          "description": "Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.",
          "timeFrame": "5 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\nINCLUSION CRITERIA AT ENROLLMENT:\n\n* Subject must be 18-60 years of age.\n* Subject must read and sign a copy of the approved Consent Form\n* Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39\n\nINCLUSION CRITERIA AT DAY -28\n\nâ€¢ Female subjects must be using an effective birth control method.\n\nINCLUSION CRITERIA AT CHALLENGE:\n\n* Female subjects must be using an effective birth control method.\n\nExclusion Criteria:\n\n* Antibiotic use within 3 months prior to day -28\n\n  * Female subjects with a positive urine pregnancy screen\n  * History of use of probiotics in the preceding two weeks\n  * Current cancer diagnosis or immunosuppressive therapy in the last 6 months\n  * Any clinically significant abnormalities of the upper respiratory tract\n  * Any clinically significant acute or chronic respiratory illness\n  * Any clinically significant bleeding tendency by history\n  * Hypertension that requires treatment with antihypertensive medications\n  * History of angina or other clinically significant cardiac disease\n  * Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study\n  * History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks\n  * History of drug or alcohol abuse in the 6 months preceding the study\n\nEXCLUSION CRITERIA AT CHALLENGE:\n\n* Any upper respiratory infection or allergic rhinitis in the two weeks prior to the challenge\n* Female subjects with positive pregnancy screen prior to challenge\n* Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study\n* Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold or allergy preparation in the two weeks prior to the challenge",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "60 Years",
      "stdAges": [
        "ADULT"
      ]
    }
  }
}